- Home
- AGFY vs IMMX Comparison
AGFY vs IMMX Comparison
Compare AGFY & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGFY
- IMMX
- Stock Information
- Founded
- AGFY 2016
- IMMX 2014
- Country
- AGFY United States
- IMMX United States
- Employees
- AGFY N/A
- IMMX N/A
- Industry
- AGFY Military/Government/Technical
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- AGFY Consumer Discretionary
- IMMX Health Care
- Exchange
- AGFY Nasdaq
- IMMX Nasdaq
- Market Cap
- AGFY 41.0M
- IMMX 44.8M
- IPO Year
- AGFY 2021
- IMMX 2021
- Fundamental
- Price
- AGFY $16.25
- IMMX $1.58
- Analyst Decision
- AGFY
- IMMX Strong Buy
- Analyst Count
- AGFY 0
- IMMX 1
- Target Price
- AGFY N/A
- IMMX $7.00
- AVG Volume (30 Days)
- AGFY 21.6K
- IMMX 56.4K
- Earning Date
- AGFY 04-14-2025
- IMMX 05-08-2025
- Dividend Yield
- AGFY N/A
- IMMX N/A
- EPS Growth
- AGFY N/A
- IMMX N/A
- EPS
- AGFY N/A
- IMMX N/A
- Revenue
- AGFY $10,385,000.00
- IMMX N/A
- Revenue This Year
- AGFY $468.67
- IMMX N/A
- Revenue Next Year
- AGFY N/A
- IMMX $600.00
- P/E Ratio
- AGFY N/A
- IMMX N/A
- Revenue Growth
- AGFY N/A
- IMMX N/A
- 52 Week Low
- AGFY $2.71
- IMMX $1.26
- 52 Week High
- AGFY $84.44
- IMMX $3.35
- Technical
- Relative Strength Index (RSI)
- AGFY 39.53
- IMMX 38.71
- Support Level
- AGFY $14.42
- IMMX $1.51
- Resistance Level
- AGFY $19.21
- IMMX $1.69
- Average True Range (ATR)
- AGFY 2.05
- IMMX 0.13
- MACD
- AGFY -0.25
- IMMX 0.00
- Stochastic Oscillator
- AGFY 24.90
- IMMX 22.16
About AGFY Agrify Corporation
Agrify Corp is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Its proprietary micro-environment-controlled Agrify Vertical Farming Units (VFUs) enable cultivators to produce high-quality products The products offered by the company include Integrated Grow Racks, LED Grow Lights, Hydroponics, and Vertical Farming Units.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.